Trial reportThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2020
Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study.
Trial report in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02224755 (Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Thoratec Corporation MOMENTUM 3, Multi-center Study of MagLev Technology in Patients Undergoing MCS Therapy With HeartMate 3™ IDE Clinical Study Protocol
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2024Pooled it
- Hemocompatibility Outcomes After Aspirin Withdrawal in Long-Term HeartMate 3 Left Ventricular Assist Device Patients on Vitamin K Antagonists.Artificial organs · 2026Article
- Short-term outcomes of pediatric HeartMate 3 left ventricular assist device: single center experience.ESC heart failure · 2026Article
- Cerebral hemorrhage after left ventricular assist device implantation in a patient with dilated cardiomyopathy: a case report.Frontiers in cardiovascular medicine · 2026Article
- Platelet microRNA Expression Can Predict Bleeding in HeartMate3 Patients Treated With or Without Aspirin.Journal of cardiovascular translational research · 2025Observational
- Prevalence, risk factors, and prognostic implications of intraoperative bleeding during CF-LVAD implant.JHLT open · 2025Article
- The Impact of Genetic Polymorphism on Complication Development in Heart Failure Patients.Journal of clinical medicine · 2024Article
- Assessment of Platelet Response to Aspirin Therapy and Hemocompatibility-Related Adverse Events in HeartMate 3 Left Ventricular Assist Device Recipients.Journal of clinical medicine · 2024Article
- Platelet reactivity is associated with pump thrombosis in patients with left ventricular assist devices.Research and practice in thrombosis and haemostasis · 2024Article
- Article
- Review
- Conservative initial postoperative anticoagulation strategy after HeartMate 3 left ventricular assist device implantation.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2022Article
- Inflow cannula position as risk factor for stroke in patients with HeartMate 3 left ventricular assist devices.Artificial organs · 2022Article
- A data mining-based cross-industry process for predicting major bleeding in mechanical circulatory support.European heart journal. Digital health · 2021Article
- Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial.European journal of heart failure · 2021Review
- Evolving perspectives on mechanical circulatory support biocompatibility and interfaces.Annals of cardiothoracic surgery · 2021Article
- Antiplatelet and anticoagulation strategies for left ventricular assist devices.Annals of translational medicine · 2021Review
- A reappraisal of the pharmacologic management of gastrointestinal bleeding in patients with continuous flow left ventricular assist devices.Heart failure reviews · 2021Review
Corrections and comments
- Commented on by
Authors and funding
13 authors at 8 institutions in 1 country.
Funding
Abstract
backgroundAspirin (ASA) anti-platelet therapy is mandated with left ventricular assist devices (LVADs) to prevent hemocompatibility-related adverse events (HRAEs). However, the optimal dose of ASA with HeartMate 3 (HM3) LVAD is unknown.
methodsIn an exploratory analysis of HM3-supported patients in the MOMENTUM 3 study (NCT02224755), 2 groups were analyzed: usual-dose (325 mg) and low-dose (81 mg) ASA with anti-coagulation targeted to an international normalized ratio of 2.0 to 3.0. Exclusion criteria included patients not receiving either ASA 81 mg or 325 mg, those with HRAEs ≤7 days after device implantation, and those receiving >1 anti-platelet agent. The primary end-point was survival free from HRAEs (non-surgical bleeding, pump thrombosis, stroke, and peripheral arterial thromboembolic events) at 2 years.
resultsOverall, 321 HM3 patients (usual-dose: n = 141, low-dose: n = 180) were included in this analysis. Usual-dose group patients were younger (57 ± 13 vs 60 ± 12 years, p = 0.035) and less often assigned destination therapy (55% vs 67%, p = 0.029) than low-dose ASA. At 2 years, a similar proportion of patients in the usual- and low-dose groups (43.4% vs 45.3%, p = 0.94) met the primary end-point. There were no differences in survival free from hemorrhagic (usual-dose: 54.4% vs low-dose: 51.7%, p = 0.42) or thrombotic (usual-dose: 76.8% vs low-dose: 75.7%, p = 0.92) events.
conclusionsUsual- and low-dose ASA revealed similar rates of bleeding and thrombotic events in HM3 LVAD-supported patients within the MOMENTUM 3 trial. Whether ASA therapy provides any meaningful therapeutic effect in patients treated by the HM3 LVAD remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.